Key result
Absence of standard cardiovascular risk factors is not associated with 30-day post-MI mortality.
Why the study?
Prior studies reported higher early mortality after acute MI in patients without standard modifiable cardiovascular risk factors, warranting further validation.
Does the absence of standard modifiable cardiovascular risk factors (SMuRFs) impact 30-day and 10-year mortality in patients with myocardial infarction?
Cohort (n=15,463)
Yes
Does the absence of standard modifiable cardiovascular risk factors (SMuRFs) impact 30-day and 10-year mortality in patients with myocardial infarction?
The absence of standard modifiable cardiovascular risk factors in MI patients does not worsen 30-day mortality, contrary to some prior reports, and is associated with improved 10-year survival.
No increased 30-day mortality risk with SMuRF absence after MI; leaves open questions on long-term prognosis in observational cohorts.
AIMS: Prior studies reported higher early mortality after acute myocardial infarction (MI) in patients without standard modifiable cardiovascular risk factors (SMuRFs), warranting further validation. We aimed to evaluate whether SMuRF-absence is associated with increased 30-day cardiovascular mortality following MI. METHODS AND RESULTS: We conducted a population-based cohort study using UK Biobank data (n = 487 177). Incident MI cases occurring between 2006 and 2022 were identified through linkage to hospital and death registries. Standard modifiable cardiovascular risk factors (diabetes, hypertension, hypercholesterolaemia, current smoker) were defined at baseline and continuously assessed until MI onset. Thirty-day mortality following MI was estimated using Cox proportional hazards models, adjusted for sociodemographic, clinical, and cardiogenomic variables, were used to estimate 30-day mortality risks. Logistic regression model was used to estimate mortality risk at 10 years post-MI. Among 15 463 patients experiencing an MI (1034 without SMuRFs), SMuRF-absence was not significantly associated with 30-day mortality (HR: 0.82, 95% CI: 0.65-1.04, P = 0.103). Propensity score-matched analyses supported these findings (HR: 0.95, 95% CI: 0.69-1.29, P = 0.729). Further analyses stratified by distinct time intervals (2006-2022) revealed no significant modification of this association by advancements in acute MI management. Interaction analyses indicated no significant effect modification by sex, age, socioeconomic status, or period of MI occurrence. However, extended analysis to 10 years revealed that SMuRF absence was significantly associated with lower long-term mortality (OR: 0.61, 95% CI: 0.49-0.75, P < 0.01). CONCLUSION: In this population-based cohort, SMuRF status significantly impacted long-term but not short-term mortality following MI, indicating early survival is predominantly driven by acute-phase factors rather than baseline cardiovascular risk profiles.
No takes yet. Share an insight, caveat, or question.
Wong et al. (2025) conducted a cohort in myocardial infarction (n=15,463). Absence of standard modifiable cardiovascular risk factors (SMuRFs) vs. Presence of standard modifiable cardiovascular risk factors was evaluated on 30-day mortality (HR 0.82, 95% CI 0.65-1.04, p=0.103). Absence of standard modifiable cardiovascular risk factors was not significantly associated with 30-day mortality following MI (HR 0.82; 95% CI 0.65-1.04; P=0.103).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: